You can narrow down the results using the filters
-
Investigating red light therapy for hypersensitive teeth during dental cleans
Fear of dental pain can produce anxiety and contribute to dental phobia. Recently, alternative methods for producing effective anaesthesia that reduce the pain experienced during dental procedures have been investigated. One such method is Photobiomodulation (PBM) which uses light to transiently block nerve transmission of pain. Clinical trials have shown that some lasers can generate analgesia using PBM. Therefore, the purpose of this study is to investigate whether a polychromatic light emitting diode (LED) device (Nuralyte®, Dentroid Canberra, Australia) can produce pulpal analgesia for hypersensitive teeth during supragingival debridements. It is hypothesised that the multiwavelength LED device (Nuralyte®, Dentroid Canberra, Australia) will be more effective when comparing the active light source to sham irradiation (single blinding for the participants). This study is being completed as part of Dr Jessica Zachar's Doctor of Philosophy (PhD) program at The University of Queensland.
-
Investigating red light therapy for pulpal analgesia during dental fillings
Fear of dental anaesthetic injection can produce anxiety and contribute to dental phobia. Recently, alternative methods for producing effective anaesthesia that reduce the pain experienced during dental procedures have been investigated. One such method is Photobiomodulation (PBM) which uses light to transiently block nerve transmission of pain. Clinical trials have shown that some lasers can generate analgesia using PBM. Therefore, the purpose of this study is to investigate whether a polychromatic light emitting diode (LED) device (Nuralyte®, Dentroid Canberra, Australia) can produce pulpal analgesia for dental restorations when compared with traditional dental local anaesthesia. It is hypothesised that the multiwavelength LED device (Nuralyte®, Dentroid Canberra, Australia) will be more effective when compared with traditional dental local anaesthesia. This study is being completed as part of Dr Jessica Zachar's Doctor of Philosophy (PhD) program at The University of Queensland.
-
S-Check 2.0: a smartphone application to address methamphetamine use in adults
This study aims to characterise the demographic and methamphetamine use profile of individuals downloading the S-Check 2.0 app, and examine associations between participant characteristics, app usage, and outcomes. Study results will inform future research and hybrid treatment options by improving understanding the characteristics of individuals that use a smartphone app as a resource for their methamphetamine use, and providing insights on how app usage is associated with changes in methamphetamine use and professional help-seeking.
-
A clinician-led feasibility, acceptability, and pilot efficacy intervention on bone health and muscle strength in people with multiple sclerosis.
This study evaluates the feasibility, acceptability, and pilot efficacy of the Onero HiRIT program in improving bone health, muscle strength and overall physical function in people with Multiple Sclerosis (MS). The primary outcomes include improvements in health-related quality of life (HR-QoL) and areal bone mineral density (aBMD), while secondary outcomes assess physical performance, mental health, and other health markers over a 24-month period. Participants will be randomly allocated to either the intervention or usual care, with a cross-over option offered after 12 months. The findings will help shape how similar programs can be utilised more widely in healthcare and community settings.
-
The Stay Strong App, Use of a Digital Wellbeing App with Indigenous People in Prison: A Randomized Controlled Trial
This study aimed to conduct a pilot trial evaluating the impact of adding the Stay Strong app (SSA) to mental health and wellbeing services for Indigenous women and men in custody. The trial compared Immediate and three month Delayed use of the app by the health service, assessing its effects on wellbeing, empowerment and psychological distress at three and six months post-Baseline.
-
Evaluating the dietary perceptions, habitual diet and diet quality of adolescents and adults with Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a rare and chronic liver disease with no proven effective medical therapies to prevent disease progression. Most patients with PSC have ulcerative colitis (UC), with potential overlapping pathophysiological mechanisms including an abnormal gut microbiota. Diet is a key fertiliser of the gut microbiota and limited evidence suggests diet may have a role is disease pathogenesis. However, there is very limited international data on the habitual diet and diet quality of adults and adolescents with PSC to inform dietary treatment targets. Therefore, this cross-sectional study will comprehensively evaluate the dietary patterns of people with PSC and understand how people who live with PSC perceive diet in disease development and progression as a first step toward informing further dietary interventions.
-
BEACON: A registry for the collection of patient-reported outcomes and the lived experience of patients with brain tumours.
The aim of this study is to establish a comprehensive registry to capture the lived experiences of patients with brain tumours. Who is it for? You may be eligible for this study if you are a male or female age 18 or older, have a brain tumour diagnosis, including but not limited to glioma, meningioma, brain metastases and rare tumours including medulloblastoma and ependymoma. Study details Participants will be asked to self register to the BEACON portal and complete questionnaires every 3 months regarding 1) Diagnosis and treatment, 2) Home supports (3) Quality of life. All data entered will be available to the participant to download after each survey is completed. It is anticipated that the surveys will take between 20 to 30 minutes to complete each time. It is hoped that BEACON will assist in determining the impact of being diagnosed with a brain tumour, from the time of diagnosis through treatment, and recurrence or progression events, and survivorship.
-
STAR-MOG: A phase III randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab during a relapse, of Myelin Oligodendrocyte Glycoprotein antibody-associated disease.
A phase III randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab during a relapse, of Myelin Oligodendrocyte Glycoprotein antibody-associated disease. Ultimately, the STAR-MOG trial will identify if two cost-effective and globally available immunotherapies can reduce relapse rates and improve outcomes of people with MOGAD, with national and global implications for clinical care.
-
A novel treatment approach targeting respiratory muscle strength in children who aspirate.
Impaired swallowing can result in food/fluids entering the lungs (aspiration), causing significant damage to developing lungs in children. Current management for aspiration in children includes change to food/fluid texture and/or enteral feeding with no specific treatments available. Respiratory muscle strength training (RMST) is effective in improving swallow function in adults with neurological diseases; however no data exists in children. The aim is to improve the management and respiratory outcomes of children who aspirate. We will conduct a study in which children will either complete respiratory muscle strength training with the RMST device or plain mask (control arm). We will see if this improves aspiration and quality of life.
-
Characteristics and outcomes of nonagenarians admitted to ICU
Australia’s population is rapidly ageing and advances in public and clinical healthcare have contributed to a near doubling in the past two decades of Australians aged over 90 years The aim of this study is to assess the characteristics and outcomes of nonagenarians admitted to an Australian Intensive Care Unit (ICU). Who is it for? You may be eligible for this study if you were aged > 90 years who has been admitted to ICU for for any indication. Study details This study will be conducted using a review of medical records, and no patient contact is required. The study will review the medical records of nonagenarians who were admitted to ICU between 1 Jan 2010 and 31 December 2020. It is hoped that this research will help to provide a better understanding of predicting risk in nonagenarians being admitted to ICU.